<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K/A
(X) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the fiscal year ended September 30, 1995
( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ________ to ________
Commission File No. 0-18734
LIDAK Pharmaceuticals
(Exact name of registrant as specified in its charter)
California 33-0314804
(State or other jurisdiction of (IRS Employer Identification No).
incorporation or organization)
11077 N. Torrey Pines Road
La Jolla, California 92037
(Address of principal executive office) (Zip Code)
(619) 558-0364
(Registrant's telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
Class A Common Stock, no par value
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities and Exchange Act
of 1934 during the preceding 12 months (or for such shorter periods that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. YES X NO
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this form 10-K or any amendment to
this form 10-K. [X]
The aggregate market value of the Registrant's voting stock, held by non-
affiliates, computed by reference to the average of the closing bid and asked
prices of the Class A Common Stock as reported by NASDAQ on December 1, 1995:
$4.3750.
The number of shares of Common Stock of the Registrant issued and outstanding
as of December 1, 1995:
Class A common stock, no par value 30,457,901
Class B common stock, no par value 283,000
DOCUMENTS INCORPORATED BY REFERENCE
Registrant's definitive Proxy Statement which will be filed with the Securities
and Exchange Commission on or before January 28, 1996 in connection with
Registrant's annual meeting of stockholders to be held on March 18, 1996 is
incorporated by reference into Part III of this Report.
<PAGE> 2
PART II
Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED
STOCKHOLDER MATTERS
The Company's shares of Class A Common Stock had traded on the NASDAQ
National Market System under the symbols LDAKA since September 30, 1993.
Previous to that date, these securities were traded on the NASDAQ Small-Cap
Market since May 8, 1990. The prices set forth below represent quotes between
dealers and do not include commissions, mark-ups or mark-downs, and may not
necessarily represent actual transactions.
Class A Common Stock
High Low
1994
First Quarter 8 1/4 4 3/4
Second Quarter 6 9/16 3 1/4
Third Quarter 3 3/8 2 3/16
Fourth Quarter 2 15/16 1 7/8
1995
First Quarter 2 1/2 1 1/2
Second Quarter 4 1/16 1 9/16
Third Quarter 4 3/4 3 1/16
Fourth Quarter 7 1/16 3 3/4
On December 1, 1995, the closing bid and ask prices of Class A Common
Stock were $4.3125 and $4.4375, respectively.
As of December 1, 1995, there were 1,032 holders of record and in excess
of 15,000 beneficial owners of the Company's Class A Common Stock. The Company
has not paid any dividends since its inception and does not contemplate payment
of dividends in the foreseeable future.
-2-
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date: December 13, 1995
LIDAK PHARMACEUTICALS
By:
Michael H. Lorber
Vice President and
Chief Financial Officer (Principal
Financial and Accounting Officer)
-3-
